Capivasertib

• A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negativ… Pending
  2025-523460-21-00 Phase II 1 country Centro Di Riferimento Oncologico Di Aviano
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting
  2025-523083-21-00 Phase III 14 countries Relay Therapeutics Inc.
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa… Recruiting
  2024-511392-15-00 Phase III 3 countries WSG Westdeutsche Studiengruppe GmbH
• Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer-… Recruiting
  2023-509292-17-00 Phase II 1 country GBG Forschungs GmbH
• NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment… Recruiting
  2023-510093-13-00 Phase II 1 country Oslo University Hospital HF
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 Phase III 3 countries Karolinska Institutet
• AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting
  2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
• Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to … Ended
  2024-513952-13-00 Phase III 1 country Astrazeneca Farmaceutica Spain S.A.
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance… Ended
  2023-504996-26-00 Phase III 8 countries AstraZeneca AB
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended
  2023-504997-39-00 Phase III 8 countries AstraZeneca AB
• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP… Ended
  2023-504998-20-00 Phase III 9 countries AstraZeneca AB
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended
  2023-505042-25-00 Phase III 7 countries AstraZeneca AB
• A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended
  2024-511646-40-00 Phase I/II 1 country AstraZeneca AB
• DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended
  2023-505690-33-00 Phase I (Other) 1 country Astrazeneca AB
• A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period… Ended
  2024-516386-36-00 Phase II 1 country AstraZeneca AB
• Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metas… Ended
  2023-505009-17-00 Phase III 1 country AstraZeneca AB

Showing 1–16 of 16 trials